FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008889418> ?p ?o ?g. }

• W2008889418 endingPage "1415" @default.
• W2008889418 startingPage "1407" @default.
• W2008889418 abstract "Bis(9-methylphenazine-1-carboxamides) joined by a variety of dicationic (CH2)nNR(CH2)mNR(CH2)n linkers of varying length (carboxamide N−N distances from 11.0 to 18.4 Å) and rigidity were prepared by reaction of 9-methylphenazine-1-carboxylic acid imidazolide with the appropriate polyamines. The compounds were evaluated for growth inhibitory properties in P388 leukemia, Lewis lung carcinoma, and wild-type (JLC) and mutant (JLA and JLD) forms of human Jurkat leukemia with low levels of topoisomerase II (topo II). The compounds all had IC50 ratios of <1 in the resistant Jurkat lines, consistent with topo II inhibition not being the primary mechanism of action. Analogues joined by an (CH2)2NR(CH2)2NR(CH2)2 linker were extremely potent cytotoxins, with selectivity toward the human cell lines, but absolute potencies declined sharply from R = H through R = Me to R = Pr and Bu. In contrast, (CH2)2NR(CH2)3NR(CH2)2 compounds showed reverse effects, with the R = Me analogue being more potent than the R = H one as well as being the most potent in the series [IC50 in JLC cells 0.08 nM; superior to that for the clinical bis(naphthalimide) LU 79553]. Overall, the IC50s of analogues with linker chains (CH2)nNH(CH2)mNH(CH2)n were inversely proportional to linker length. Constraining the rigidity of the linker chain by incorporating a piperazine ring did not decrease potency significantly. A representative compound bound tightly to DNA with high selectivity for GC sites, compatible with recent work suggesting that compounds of this type place their side chains in the major groove, making specific contacts with guanine bases. Representative compounds were susceptible to transport mediated resistance, being much less effective in cells that overexpressed P-glycoprotein. Overall the results suggest these compounds have a similar mode of action, mediated primarily by poisoning of topo I (possibly with some involvement of topo II). The bis(9-methylphenazine-1-carboxamides) show very high in vitro growth inhibitory potencies compared to their monomeric analogues. Two compounds showed in vivo activity in murine colon 38 syngeneic and HT29 human colon tumor xenograft models using intraperitoneal dosing." @default.
• W2008889418 created "2016-06-24" @default.
• W2008889418 creator A5023901201 @default.
• W2008889418 creator A5031189811 @default.
• W2008889418 creator A5046235145 @default.
• W2008889418 creator A5051183042 @default.
• W2008889418 creator A5061684371 @default.
• W2008889418 creator A5068021335 @default.
• W2008889418 creator A5078335153 @default.
• W2008889418 date "2001-03-28" @default.
• W2008889418 modified "2023-09-24" @default.
• W2008889418 title "Dicationic Bis(9-methylphenazine-1-carboxamides): Relationships between Biological Activity and Linker Chain Structure for a Series of Potent Topoisomerase Targeted Anticancer Drugs" @default.
• W2008889418 cites W1971079311 @default.
• W2008889418 cites W1972410555 @default.
• W2008889418 cites W1974839286 @default.
• W2008889418 cites W1980782542 @default.
• W2008889418 cites W1997241897 @default.
• W2008889418 cites W2006621064 @default.
• W2008889418 cites W2024071413 @default.
• W2008889418 cites W2034660754 @default.
• W2008889418 cites W2038909709 @default.
• W2008889418 cites W2044714528 @default.
• W2008889418 cites W2047893495 @default.
• W2008889418 cites W2052121423 @default.
• W2008889418 cites W2057440410 @default.
• W2008889418 cites W2086384710 @default.
• W2008889418 cites W2088188015 @default.
• W2008889418 cites W2109689528 @default.
• W2008889418 cites W2144067671 @default.
• W2008889418 cites W2155208683 @default.
• W2008889418 cites W2164040629 @default.
• W2008889418 cites W2319287459 @default.
• W2008889418 cites W2950740969 @default.
• W2008889418 cites W2950938499 @default.
• W2008889418 cites W2951808611 @default.
• W2008889418 doi "https://doi.org/10.1021/jm0003283" @default.
• W2008889418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11311063" @default.
• W2008889418 hasPublicationYear "2001" @default.
• W2008889418 type Work @default.
• W2008889418 sameAs 2008889418 @default.
• W2008889418 citedByCount "56" @default.
• W2008889418 countsByYear W20088894182012 @default.
• W2008889418 countsByYear W20088894182013 @default.
• W2008889418 countsByYear W20088894182014 @default.
• W2008889418 countsByYear W20088894182016 @default.
• W2008889418 countsByYear W20088894182017 @default.
• W2008889418 countsByYear W20088894182018 @default.
• W2008889418 countsByYear W20088894182020 @default.
• W2008889418 countsByYear W20088894182021 @default.
• W2008889418 countsByYear W20088894182022 @default.
• W2008889418 crossrefType "journal-article" @default.
• W2008889418 hasAuthorship W2008889418A5023901201 @default.
• W2008889418 hasAuthorship W2008889418A5031189811 @default.
• W2008889418 hasAuthorship W2008889418A5046235145 @default.
• W2008889418 hasAuthorship W2008889418A5051183042 @default.
• W2008889418 hasAuthorship W2008889418A5061684371 @default.
• W2008889418 hasAuthorship W2008889418A5068021335 @default.
• W2008889418 hasAuthorship W2008889418A5078335153 @default.
• W2008889418 hasConcept C109316439 @default.
• W2008889418 hasConcept C111919701 @default.
• W2008889418 hasConcept C118792377 @default.
• W2008889418 hasConcept C147897179 @default.
• W2008889418 hasConcept C161790260 @default.
• W2008889418 hasConcept C179464577 @default.
• W2008889418 hasConcept C185592680 @default.
• W2008889418 hasConcept C193042331 @default.
• W2008889418 hasConcept C202751555 @default.
• W2008889418 hasConcept C203014093 @default.
• W2008889418 hasConcept C2776090121 @default.
• W2008889418 hasConcept C2778327999 @default.
• W2008889418 hasConcept C2780557392 @default.
• W2008889418 hasConcept C41008148 @default.
• W2008889418 hasConcept C552990157 @default.
• W2008889418 hasConcept C55493867 @default.
• W2008889418 hasConcept C71240020 @default.
• W2008889418 hasConcept C86803240 @default.
• W2008889418 hasConcept C8891405 @default.
• W2008889418 hasConceptScore W2008889418C109316439 @default.
• W2008889418 hasConceptScore W2008889418C111919701 @default.
• W2008889418 hasConceptScore W2008889418C118792377 @default.
• W2008889418 hasConceptScore W2008889418C147897179 @default.
• W2008889418 hasConceptScore W2008889418C161790260 @default.
• W2008889418 hasConceptScore W2008889418C179464577 @default.
• W2008889418 hasConceptScore W2008889418C185592680 @default.
• W2008889418 hasConceptScore W2008889418C193042331 @default.
• W2008889418 hasConceptScore W2008889418C202751555 @default.
• W2008889418 hasConceptScore W2008889418C203014093 @default.
• W2008889418 hasConceptScore W2008889418C2776090121 @default.
• W2008889418 hasConceptScore W2008889418C2778327999 @default.
• W2008889418 hasConceptScore W2008889418C2780557392 @default.
• W2008889418 hasConceptScore W2008889418C41008148 @default.
• W2008889418 hasConceptScore W2008889418C552990157 @default.
• W2008889418 hasConceptScore W2008889418C55493867 @default.
• W2008889418 hasConceptScore W2008889418C71240020 @default.
• W2008889418 hasConceptScore W2008889418C86803240 @default.
• W2008889418 hasConceptScore W2008889418C8891405 @default.
• W2008889418 hasIssue "9" @default.
• W2008889418 hasLocation W20088894181 @default.

• next